Skip to main content
. 2018 Jan 31;13(1):e0192180. doi: 10.1371/journal.pone.0192180

Fig 4. Chemical inhibition of ABCC6 increases the efficacy of dasatinib but not imatinib in BCR-ABL1+ cell lines.

Fig 4

(A,E) K562 (B,F) K562-Dox (C,G) K562-ABCG2 and (D,H) KU812 cells were incubated with the indicated concentrations of (A-D) dasatinib and (E-H) imatinib in the absence and presence of three ABCC6 inhibitors (200 μM pantoprazole, 100 μM indomethacin, 1 mM probenecid). CRKL western blotting was performed to determine the concentration of TKI required for 50% Bcr-Abl kinase inhibition (IC50). Error bars represent SEM. Representative western blots are shown in S3 and S4 Figs. IM = imatinib; DAS = dasatinib; PP = pantoprazole; Indo = Indomethacin; Pro = probenecid.